Medical Equipment Supplies
Clinical Diagnostic Laboratory
Supplies are provided in the following areas: biochemistry, hematology, glycated hemoglobin, immunochemistry, hemostasis, blood gas analysis, urinalysis, ESR, PCR, immunohematology, microbiology, mass spectrometry, pathomorphology
Equipment and reagent manufacturers: DIRUI (China), Lifotronic (China), BioRad (USA), Lidlab (Russia), Snibe (China), Werfen (Germany), STAGO (France, USA), Technology Standard (Russia), EDAN (China), Alifax (Italy), Amplitec (Russia), Medcaptain (China), Meihua (China), Autobio (China), Lituo (China), Shimadzu (Japan), Becton, Dickinson (USA), bioMérieux (France), Beckman Coulter (USA), Abbott (USA) and others
Neonatology
Equipment and consumables are supplied for: compounders, resuscitation stations, incubators, phototherapy, ventilators, oxygen therapy, fetal monitors, PICC catheters
Equipment and consumables manufacturers: Impromediform (Germany), Tosan (Iran), Respircare (China), Fisher & Paykel Healthcare Limited (New Zealand), HAMILTON MEDICAL (New Zealand), EDAN (China), Vivoline (Russia)
Diagnostics and Therapy
Supplies are provided in the following areas: gastroscopy, colonoscopy, bronchoscopy, endoscopic ultrasound, artificial intelligence in endoscopy, mammography, X-ray equipment, ultrasound, cardiographs, ENT units, audiometers, tympanometers, clean rooms, telemedicine, suture materials, skin staplers, surgical instruments
Equipment manufacturers: Fujifilm (Japan), Alpinion (Korea), EDAN (China), Canon (Japan), Otopront (Germany), HILBRO (Pakistan), Hospital Technik (Russia), Tion (Russia), Orelmedtech (Russia), Katsan (Turkey) and others
Equipment for R&D
Supplies are provided in the following areas: cell technologies, cell biology, biobank, genetics and equipment for molecular genetic research
Scientific Activities
Development of preparations based on bacteriophage complexes for rational prevention and treatment of bacterial infections in conditions of limited antibiotic use.
Development of preparations based on bacteriophage complexes for decontamination and extending shelf life of animal products (bioprocessing) and reducing the risk of infectious diseases in humans.
Why These Directions Matter
By 2050, global mortality from antibiotic resistance will exceed the combined mortality from cancer and diabetes.
*According to calculations from the British study Review on Antimicrobial Resistance
The concept of LifePhage's scientific activities aims to address the following issues:
The growth of antibiotic resistance in microorganisms and, consequently, an increase in the level of superinfections and economic damage;
The lack of safe and simultaneously effective means of protecting humans and animals for the treatment and prevention of infectious diseases;
The search for and application of effective alternative antibacterial agents of natural origin in agriculture and production (food safety).
About Bacteriophages
The introduction of antibiotics in the mid-20th century for the treatment of infectious diseases revolutionized medicine. Unfortunately, both improper and proper use of antibiotics led to the formation and spread of resistance to these drugs in pathogenic microorganisms, which is associated with reduced treatment effectiveness and, consequently, more severe and prolonged course of diseases, increased frequency of patient hospitalizations, increased mortality, and increased economic damage to society.
Any methods of using antibiotics in humans, animals, or plants can lead to the formation and spread of antibiotic resistance. Moreover, antibiotic resistance does not recognize any geographical or biological boundaries. Thus, the use of antibiotics in some industries, conditions, or countries affects the spread of resistance to them in other industries, conditions, or countries. Resistance to various classes of antibiotics is steadily increasing in various types of bacteria, as well as in various environmental conditions. Thus, previously effective antibiotics are losing their power, and medicine is returning to the situation that existed in the pre-antibiotic era. The importance of antibiotics as life-saving drugs is under threat.
New means of combating bacteria are needed more than ever - ordinary people suffer from the current situation first and foremost.
Bacteriophages are viruses that infect bacterial cells. Bacteriophages represent the most numerous, widely distributed group of viruses in the biosphere and are presumed to be the most evolutionarily ancient group of viruses.
The use of bacteriophage-based preparations is possible for all age groups, including pregnant women and newborns, and phage therapy has no side effects. Unlike antibiotics, which affect all microorganisms, including beneficial ones, bacteriophages act selectively only against the target bacteria and do not cause the death of beneficial microflora.
The development and implementation of bacteriophage preparations for the treatment and prevention of infectious diseases caused by pathogenic microflora resistant to various types of antibiotics can be an effective replacement for current global trends in antibiotic use.
